Product Description
a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25885172/)
Mechanisms of Action: GK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes
Phase 1: Type 2 Diabetes|Overweight|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| B1621018 | P1 |
Completed |
Type 2 Diabetes |
2015-03-01 |
2019-03-20 |
Treatments |
|
| JapicCTI-142719 | P1 |
Unknown |
Type 2 Diabetes |
2015-03-01 |
|||
| B1621015 | P1 |
Completed |
Type 2 Diabetes |
2015-01-01 |
2019-03-20 |
Treatments |
|
| B1621019 | P1 |
Completed |
Type 2 Diabetes |
2014-03-01 |
2019-03-19 |
Treatments |
|
| B1621005 | P1 |
Completed |
Overweight |
2012-02-01 |
2019-03-19 |
Treatments |
|
| B1621011 | P1 |
Completed |
Healthy Volunteers |
2011-10-01 |
2019-03-19 |
Treatments |
|
| B1621003 | P1 |
Completed |
Type 2 Diabetes |
2011-07-01 |
2019-03-19 |
Treatments |
|
| B1621001 | P1 |
Completed |
Type 2 Diabetes |
2010-05-01 |
2019-03-19 |
Treatments |
|
| 12 WEEK POC IN T2DM WITH GLIMEPIRIDE | P2 |
Completed |
Type 2 Diabetes |
2013-01-28 |
2022-03-13 |
Treatments |
|
| 12 WEEK POC IN T2DM WITH SITAGLIPTIN | P2 |
Completed |
Type 2 Diabetes |
2013-01-24 |
2025-06-29 |
Treatments |
|
| B1621007 | P2 |
Completed |
Type 2 Diabetes |
2013-01-01 |
2019-03-19 |
Treatments |
|
| B1621002 | P2 |
Completed |
Type 2 Diabetes |
2013-01-01 |
2019-03-19 |
Treatments |